Telix Pharmaceuticals
A$14.64
103
-A$0.29-1.91% Friday 06:10
Statistics
Day High
15.28
Day Low
14.6
52W High
29.32
52W Low
8.63
Volume
80,723,460
Avg. Volume
-
Mkt Cap
4.96B
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
19FebExpected
Expected EPS
0.046411506469999995
Actual EPS
-0.016430355999999997
Financials
-0.89%Profit Margin
Unprofitable1.61BRevenue
-14.25MNet Income
Analyst Ratings
24.76Average Price Target
The highest estimate is 25.92.
From 3 ratings within the last 6 months. This is not an investment recommendation.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow TLX.AU. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Alternative Access First Priority CLO Bond
AAA
Mkt Cap0
ClearPoint Neuro
CLPT
Mkt Cap258.22M
Novartis
NVS
Mkt Cap297.35B
Bausch Health Companies
BHC
Mkt Cap2.09B
Protagonist Therapeutics
PTGX
Mkt Cap6.31B
Dr. Reddy`s Laboratories
RDY
Mkt Cap11.11B
Bristol-Myers Squibb
BMY
Mkt Cap119.69B
Lilly(Eli) &
LLY
Mkt Cap840.84B
Pfizer
PFE
Mkt Cap153.13B
About
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Show more...
CEO
Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., Ph.D
Employees
1120
Country
Australia
ISIN
AU000000TLX2
Listings
0 Comments
Share your thoughts
FAQ
What is Telix Pharmaceuticals stock price today?▼
The current price of TLX.AU is A$14.64 AUD — it has decreased by -1.91% in the past 24 hours. Watch Telix Pharmaceuticals stock price performance more closely on the chart.
What is Telix Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Telix Pharmaceuticals stocks are traded under the ticker TLX.AU.
Is Telix Pharmaceuticals stock price growing?▼
TLX.AU stock has risen by +0% compared to the previous week, the month change is a +17.97% rise, over the last year Telix Pharmaceuticals has showed a -43.01% decrease.
What is Telix Pharmaceuticals market cap?▼
Today Telix Pharmaceuticals has the market capitalization of 4.96B
When is the next Telix Pharmaceuticals earnings date?▼
Telix Pharmaceuticals is going to release the next earnings report on August 20, 2026.
What were Telix Pharmaceuticals earnings last quarter?▼
TLX.AU earnings for the last quarter are -0.02 AUD per share, whereas the estimation was 0.05 AUD resulting in a -135.4% surprise. The estimated earnings for the next quarter are N/A AUD per share.
What is Telix Pharmaceuticals revenue for the last year?▼
Telix Pharmaceuticals revenue for the last year amounts to 1.61B AUD.
What is Telix Pharmaceuticals net income for the last year?▼
TLX.AU net income for the last year is -14.25M AUD.
How many employees does Telix Pharmaceuticals have?▼
As of April 19, 2026, the company has 1,120 employees.
In which sector is Telix Pharmaceuticals located?▼
Telix Pharmaceuticals operates in the Health & Wellness sector.
When did Telix Pharmaceuticals complete a stock split?▼
Telix Pharmaceuticals has not had any recent stock splits.
Where is Telix Pharmaceuticals headquartered?▼
Telix Pharmaceuticals is headquartered in North Melbourne, Australia.